Syndax Pharmaceuticals (SNDX) News Today $9.63 -0.36 (-3.60%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$9.64 +0.00 (+0.05%) As of 07/25/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNDX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Sells $12,039.84 in StockJuly 19, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Sells $69,990.86 in StockJuly 19, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith A. Goldan Sells 1,296 SharesJuly 19, 2025 | insidertrades.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $34.10 Consensus Price Target from AnalystsJuly 19, 2025 | americanbankingnews.comVienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Makes New $2.46 Million Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)July 18, 2025 | marketbeat.comUBS Group Cuts Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $35.00July 18, 2025 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6% Following Analyst DowngradeJuly 17, 2025 | americanbankingnews.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 16, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 6% on Analyst DowngradeJuly 15, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $35.00 by Analysts at UBS GroupJuly 15, 2025 | marketbeat.com3 ‘Strong Buy’ Russell 2000 Stocks with Triple-Digit Upside PotentialJuly 12, 2025 | msn.comThe Goldman Sachs Group Initiates Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX)July 10, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 6.7% - Time to Buy?July 9, 2025 | marketbeat.comSyndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AMLJuly 9, 2025 | msn.comSyndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug ApprovalsJuly 8, 2025 | seekingalpha.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)July 2, 2025 | globenewswire.comSyndax Pharmaceuticals, Inc. (SNDX) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comSNDX Syndax Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comSyndax Pharmaceuticals Inc News (SNDX) - Investing.comJune 26, 2025 | investing.comSyndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia - MorningstarJune 25, 2025 | morningstar.comMSyndax Gets Priority Review for Leukemia Drug ApplicationJune 24, 2025 | marketwatch.comSyndax stock rises after FDA grants Priority Review for cancer drug expansionJune 24, 2025 | investing.comSyndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML TrialJune 24, 2025 | msn.comSyndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid LeukemiaJune 24, 2025 | globenewswire.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 21, 2025 | marketbeat.comSyndax reports publication of revumenib data from BEAT AML trialJune 13, 2025 | msn.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Assenagon Asset Management S.A.June 13, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.7% - Time to Sell?June 12, 2025 | marketbeat.comSyndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025June 12, 2025 | globenewswire.comSyndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025June 12, 2025 | globenewswire.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 7, 2025 | marketbeat.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 5, 2025 | globenewswire.comAmeriprise Financial Inc. Has $423,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)June 5, 2025 | marketbeat.comNuveen Asset Management LLC Trims Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)June 1, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Bank of America Corp DEJune 1, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Wellington Management Group LLPMay 31, 2025 | marketbeat.comVoloridge Investment Management LLC Takes $1.05 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 31, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 4.9% - Still a Buy?May 30, 2025 | marketbeat.comSyndax Announces Participation in June Investor ConferencesMay 29, 2025 | globenewswire.comPolar Asset Management Partners Inc. Invests $1.12 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 29, 2025 | marketbeat.comMillennium Management LLC Has $7.76 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 28, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Two Sigma Investments LPMay 27, 2025 | marketbeat.comTwo Sigma Advisers LP Has $7.09 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 26, 2025 | marketbeat.com121,539 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Acquired by Man Group plcMay 26, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 5.7% - Here's WhyMay 25, 2025 | marketbeat.comTwinbeech Capital LP Boosts Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 23, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Lowers Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 23, 2025 | marketbeat.comSoleus Capital Management L.P. Boosts Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 21, 2025 | marketbeat.comSyndax Pharmaceuticals Inc.May 21, 2025 | wsj.com Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address SNDX Media Mentions By Week SNDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNDX News Sentiment▼1.481.07▲Average Medical News Sentiment SNDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNDX Articles This Week▼46▲SNDX Articles Average Week Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HCM News IMVT News KYMR News CRNX News MOR News ALVO News MIRM News CPRX News AMRX News NAMS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNDX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
